Search
Clinician Ordering Portal
Scientific evidence
A cost-effectiveness analysis of an adenocarcinoma risk prediction multi-biomarker assay for patients with Barrett’s esophagus
Oct 2019
The TissueCypher assay would be cost-effective after five years and improves patient outcomes by improving effectiveness of surveillance and treatment protocols.
Publication: ClinicoEconomics and Outcomes Research
An automated, quantitative multiplex immunofluorescence assay accurately risk stratifies Barrett’s esophagus patients with a community-based diagnosis of low-grade dysplasia at a rate comparable to expert pathologists
Oct 2019
TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.
Publication: Poster presentation (372) at ACG 2019, San Antonio
An automated, quantitative multiplex immunofluorescence assay accurately risk stratifies Barrett’s esophagus patients with a community-based diagnosis of low-grade dysplasia at a rate comparable to expert pathologists
Oct 2019
TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.
Publication: Poster presentation (P1990) at UEG 2019, Barcelona
Impact of gene expression profile testing on the management of squamous cell carcinoma by dermatologists
Oct 2019
To determine the impact of cSCC-GEP test results on management decisions made by dermatologists for cSCC patients.
Publication: JDD
An automated, quantitative multiplex immunofluorescence assay accurately risk stratifies Barrett’s esophagus patients with a community-based diagnosis of low grade dysplasia at a rate comparable to expert pathologists
Oct 2019
TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.
Publication: Poster presentation (372) at ACG 2019, San Antonio
Evaluation of additional spatial and temporal information increases the overall accuracy of an objective risk prediction assay in patients with non-dysplastic Barrett’s esophagus
Oct 2019
TissueCypher may be an effective solution to aid decision-making on surveillance intervals and therapeutic interventions in the management of NDBE patients.
Publication: Poster presentation (371) at ACG 2019, San Antonio
Appropriate use criteria for the integration of diagnostic and prognostic gene expression profile assays into the management of cutaneous malignant melanoma: an expert panel consensus-based modified delphi process assessment
Sep 2019
Expert panel of 9 dermatologists developed 29 clinical scenarios creating an evidence based framework for AUC recommendations for integration of melanoma GEP tests into clincial practice.
Publication: SKIN: Journal of Cutaneous Melanoma
Level of evidence review for a gene expression profile test for cutaneous melanoma
Jul 2019
Review the current literature and establish the level of evidence for a cutaneous melanoma 31-GEP test.
Publication: American Journal of Clinical Dermatology
Establishing an evidence-based decision point for clinical use of the 31-gene expression profile test in cutaneous melanoma
Jul 2019
Multi center study establishing appropriate use criteria for determining risk of recurrence in patients with tumors >0.3mm in thickness.
Publication: SKIN: Journal of Cutaneous Melanoma
Independent validation of a tissue systems pathology test to predict progression in Barrett’s esophagus patients
May 2019
TissueCypher identifies NDBE patients who are at increased risk for progression to HGD/EAC and may benefit from increased surveillance or early intervention.
Publication: Podium presentation (1068) at DDW 2019, San Diego
Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma
Apr 2019
Independent, prospective study with over 3.5 years of follow-up, showing results consistent with previous validation studies with GEP class score as statistically associated with MSS, DMFS and RFS.
Publication: Cancer Medicine
Correlation of melanoma gene expression score with clinical outcomes on a series of melanocytic lesions
Apr 2019
Clinical validation study of the 23-GEP in lesions with clinical outcomes and follow-up data.
Publication: Human Pathology